. 2024 Jun 1;35(6):423–439. doi: 10.5152/tjg.2024.24029
Content of this journal is licensed under a Table 2.
Medical Therapy in Irritable Bowel Syndrome (Modified from reference10)
| IBS with Predominant Constipation (IBS-C) | IBS with Predominant Diarrhea (IBS-D) | Abdominal Pain |
|---|---|---|
| Psyllium | Low-FODMAP diet | Low-FODMAP diet |
| PEG, laxatives | Loperamide | |
| Antispasmodics | Antispasmodics | Antispasmodics Mint oil |
| SSRI | TCA | TCA |
| Rifaximin | ||
| Guanylate cyclase C agonists(linaclotide/plecanatide) | 5-HT3 receptor antagonists (ondansetron) | |
| 5-HT 4 receptor agonists | Bile acid sequestrants | |
| Intestinal Cl channel activator (lubiprostone) | Eluxadoline | |
| Na-H exchange inhibitor(tenapanor) |
Psychotherapy: cognitive behavioral therapy/gut hypnotherapy.
IBS, irritable bowel syndrome; FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; PEG, polyethylene glycol; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressants.